X
[{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbrium Therapeutics Presents First Data and Describes Novel Mechanism of Action For IMB-115","therapeuticArea":"Sleep","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Sleep","graph2":"Phase I"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"PureTech Health","pharmaFlowCategory":"D","amount":"$59.5 million","upfrontCash":"Undisclosed","newsHeadline":"PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503\/IMB-150 for Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Urology","graph2":"Preclinical"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Imbrium Therapeutics Completes First Patient Visit in Phase 1 Study of Potential Treatment for Interstitial Cystitis\/Bladder Pain Syndrome","therapeuticArea":"Urology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Urology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Imbrium Therapeutics
Filters
Companies By Therapeutic Area
Details:
IMB-150 (also known as LYT-503) as a potential non-opioid treatment for female patients with Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). IMB-150, is a novel formulation of lidocaine, and the clinical development program is called GainMe-IC.
Lead Product(s):
IMB-150
Therapeutic Area: Urology
Product Name: LYT-503
Highest Development Status: Phase I
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 20, 2022
Details:
Under the terms of the agreement, Imbrium is responsible for all future development activities and funding for LYT-503/IMB-150, for which an IND filing is planned for early 2022.
Lead Product(s):
IMB-150
Therapeutic Area: Urology
Product Name: LYT-503
Highest Development Status: Preclinical
Product Type: Large molecule
Recipient:
PureTech Health
Deal Size: $59.5 million
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
August 11, 2021
Details:
IMB-115 is a novel, highly potent and selective partial agonist for nociceptin/orphanin-FQ peptide (NOP) receptors designed to promote sleep onset and maintenance at doses that show minimal or no residual next-day somnolence (drowsiness) or psychomotor impairment.
Lead Product(s):
IMB-115
Therapeutic Area: Sleep
Product Name: IMB-115
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 28, 2020